GLG News by Physicians who Specialize in Alcohol Withdrawal

The reality that the actual details of the ENHANCE have not been circulated and that alternate explanations or caveats may be raised is probably unimportant.   The bottom line carries the day and the bottom line is that the trial's title, ENHANCE, was not achieved by the addition of VYTORIN when...

The notion that Lilly is promulgating here by marketing Cialis as a daily preparation is that you can have it both ways, namely always being prepared for sexual relations that are spontaneous.  From an observer of the human comedy (me), this will sell very well as the Baby Boom ages.  No mention...

Allosteric modulation of the metabotropic glutamate receptor 5 (mGluR5) for treatment of schizophrenia seems highly promising from a basic science perspective.  It has not been well tested in the clinic yet.  The fact that two major pharmaceutical firms are now in the hunt towards clinical...

An interesting observation made as a consequence of the widespread use of serotonin specific reuptake inhibitors (SSRI) in clinical psychiatry is that these medications tend to affect appetite.  SSRIs can cause either weight gain or loss.  There was a time when they were extensively used in...

Lu AA21004 is a new "bis-aryl-sulphanyl modulator" that has both preclinical and clinical support for future development for market as an "affective modulator". (I use the term affective modulator because I doubt whether the ultimate indication for this agent will be based on anxiety or depression.) ...

Helping regenerate or preventing death of dopaminergic neurons in the motor system is novel and exciting.  That is the strategy described in the accomapanying clinical trial of insertion of a nerve growth factor gene into the putamen of patients with Parkinson’s disease—a region of the brain affected...

Here we go again; look at all metabolites of a successful drug for efficacy to increase your bang for the corporate buck.  Brilliant--because success is virtually assured at relatively little cost.  Venlafaxine is a reasonably good antidepressant, and in my experience, useful except in...

At this stage there is a paucity of antidepressants that are approved in adolescent depression, even though antidepressants were perhaps excessively used until the recent concern over their increasing suicide risk.  So it is a very good strategy to extend patent somewhat by cornering the adolescent...

We have been hoping that remonibant, the cannabinoid antagonist, would allow patients with obesity to lose weight "pharmacologically" without actually having to undergo the significant effort to reverse a lifetime of self-destructive behaviors that have culminated in pathological obesity--obesity that...

It is a good idea to have FDA approval for disorders in children because this aspect of the pharmacopea is not well developed.  Aripiprazole is an atypical "atypical" neuroleptic that will likely have some beneficial effects in behavioral dyscontrol, but is not likely specific to bipolar I disorder. ...